Clinicopathological Characteristics and Long-term Prognosis of Screening Detected Non-palpable Breast Cancer by Ultrasound in Hospital-based Chinese Population (2001-2014)
Overview
Authors
Affiliations
Purpose: The mainstay modality of breast cancer screening in China is the hospital-based opportunistic screening among asymptomatic self-referred women. There is little data about the ultrasound (US) detected non-palpable breast cancer (NPBC) in Chinese population.
Methods: We analyzed 699 consecutive NPBC from 1.8-2.3 million asymptomatic women from 2001 to 2014, including 572 US-detected NPBC from 3,786 US-positive women and 127 mammography (MG) detected NPBC from 788 MG-positive women. The clinicopathological features, disease-free survival (DFS) and overall survival (OS) were compared between the US- and MG-detected NPBC. Prognostic factors of NPBC were identified.
Results: Compared to MG, US could detect more invasive NPBC (83.6% vs 54.3%, p<0.001), lymph node positive NPBC (19.1% vs 10.2%, p=0.018), lower grade (24.8% vs 16.5%, p<0.001), multifocal (19.2% vs 6.3%, p<0.001), PR positive (71.4% vs 66.9%, p=0.041), Her2 negative (74.3% vs 54.3%, p<0.001), Ki67 high (defined as >14%, 46.3% vs 37.0%, p=0.031) cancers and more NPBC who received chemotherapy (40.7% vs 21.3%, p<0.001). There was no significant difference in 10-year DFS and OS between US-detected vs MG-detected NPBC, DCIS and invasive NPBC. For all NPBC and the US-detected NPBC, the common DFS-predictors included pT, pN, p53 and bilateral cancers.
Conclusion: US could detect more invasive, node-positive, multifocal NPBC in hospital-based asymptomatic Chinese female, who could achieve comparable 10-year DFS and OS as MG-detected NPBC. US would not delay early detection of NPBC with improved cost-effectiveness, thus could serve as the feasible initial imaging modality in hospital-based opportunistic screening among Chinese women.
Pan B, Xu Y, Zhou Y, Yao R, Zhou X, Xu Y Breast Cancer Res Treat. 2022; 196(2):409-422.
PMID: 36166112 PMC: 9581860. DOI: 10.1007/s10549-022-06747-5.
Zhang Q, Zhang Q, Liu T, Bao T, Li Q, Yang Y Front Oncol. 2022; 12:868164.
PMID: 35463357 PMC: 9021381. DOI: 10.3389/fonc.2022.868164.
Zhao C, Xiao M, Ma L, Ye X, Deng J, Cui L Front Oncol. 2022; 12:804632.
PMID: 35223484 PMC: 8867611. DOI: 10.3389/fonc.2022.804632.
Xiao M, Zhao C, Li J, Zhang J, Liu H, Wang M Front Oncol. 2020; 10:1070.
PMID: 32733799 PMC: 7358588. DOI: 10.3389/fonc.2020.01070.
Xiao M, Zhao C, Zhu Q, Zhang J, Liu H, Li J J Thorac Dis. 2020; 11(12):5023-5031.
PMID: 32030218 PMC: 6988000. DOI: 10.21037/jtd.2019.12.10.